Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Sangeeta Sawhney, MD
Intercept Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
346 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital Gastroenterology and Hepatology Dept.
Adelaide, Australia
- Flinders Medical Centre
Bedford Park, Australia
- Aw Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital
Camperdown, Australia
- Monash Health - Monash Medical Centre
Clayton, Australia
- Gallipoli Medical Research Foundation
Greenslopes, Australia
- Austin Hospital
Heidelberg, Australia
- Royal Brisbane and Women'S Hospital
Herston, Australia
- Nepean Hospital
Kingswood, Australia
- the Alfred Hospital, Department of Gastroenterology
Melbourne, Australia
- Fiona Stanley Hospital
Murdoch, Australia
- the Royal Melbourne Hospital
Parkville, Australia
- Westmead Hospital
Westmead, Australia
- Universitätsklinik Für Innere Medizin I Innsbruck
Innsbruck, Austria
- Klinikum Klagenfurt Am Wörthersee
Klagenfurt, Austria
- Ordensklinikum Linz Gmbh
Linz, Austria
- Uniklinikum Salzburg
Salzburg, Austria
- Medizinische Universität Wien
Vienna, Austria
- Uz Antwerpen
Edegem, Antwerpen, Belgium
- Ulb Hȏpital Erasme - Gastroenterology
Brussels, Brabant, Belgium
- Uz Leuven Campus Gathuisberg Hepatology Department
Leuven, Vlaams-Brabant, Belgium
- Az Sint-Jan Brugge Oostende
Bruges, Belgium
- Ucl Saint-Luc - Hepatology Department
Brussels, Belgium
- Ziekenhuis Oost-Limburg (zol)
Genk, Belgium
- Uz Gent Gastroenterology Department
Ghent, Belgium
- Az Nikolaas
Sint-Niklaas, Belgium
- London Health Sciences Centre University Hospital
London, Ontario, Canada
- University of Calgary Liver Unit
Calgary, Canada
- Gi Research
Edmonton, Canada
- University of Alberta
Edmonton, Canada
- Centre de Recherche Du Centre Hospitalier de L'Universite de Montreal
Montreal, Canada
- the Research Institute of the Mcgill University Health Centre
Montreal, Canada
- Toronto Center for Liver Disease
Toronto, Canada
- Toronto Liver Centre
Toronto, Canada
- Giri - Gi Research Institute
Vancouver, Canada
- Gordon and Leslie Diamond Health Care Centre
Vancouver, Canada
- Lair Centre
Vancouver, Canada
- Percuro Clinical Research Ltd.
Victoria, Canada
- John Buhler Research Centre
Winnipeg, Canada
- Aalborg University Hospital
Aalborg, Denmark
- Aarhus University Hospital Medicinsk Hepatogastroenterologisk Afdeling
Aarhus, Denmark
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Sept 2015
- Primary completion
- 15 Sept 2023
- Completion
- 15 Sept 2023
- Last update posted
- 1 Oct 2024
- Registered enrollment
- 2,477
- Registry id
- NCT02548351
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.